Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA approves Enhertu for two HER2-positive early breast cancer indications
In the neoadjuvant setting, the therapy is approved for adults with HER2-positive stage 2 or stage 3 breast cancer. Credit: Arif biswas / Shutterstock.com.
In the neoadjuvant setting, the therapy is approved for adults with HER2-positive stage 2 or stage 3 breast cancer. Credit: Arif biswas / Shutterstock.com.